Announcements Trials

Browse Landscape

Phase

Status

Recruiting 7 Completed 3 Unknown 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1127 Neoplasms 982 Carcinoma, Non-Small-Cell Lung 900 Prostatic Neoplasms 594 Neoplasm Metastasis 528 Leukemia, Myeloid, Acute 513 Colorectal Neoplasms 491 Lung Neoplasms 487 Melanoma 485 Multiple Myeloma 477 Pancreatic Neoplasms 385 Lymphoma 369 Ovarian Neoplasms 368 Recurrence 365 Lymphoma, Non-Hodgkin 346 Leukemia 339 Leukemia, Lymphocytic, Chronic, B-Cell 321 Precursor Cell Lymphoblastic Leukemia-Lymphoma 291 Head and Neck Neoplasms 276 Carcinoma, Renal Cell 276 Brain Neoplasms 273 Carcinoma, Hepatocellular 261 Glioblastoma 249 Lymphoma, Large B-Cell, Diffuse 244 Myelodysplastic Syndromes 242 Squamous Cell Carcinoma of Head and Neck 241 Lymphoma, Follicular 236 Colonic Neoplasms 214 Stomach Neoplasms 200 Rectal Neoplasms 190

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡